Fate Therapeutics to Present at the 5th Annual Cell & Gene Therapy Investor DayGlobeNewswire (press release)SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to… Continue reading
The San Diego Union-Tribune |
Should Californians give more money for stem cell research?
The San Diego Union-Tribune Are Californians getting their money’s worth for the $3 billion they invested in stem cell science in 2004? Is there cause for optimism that major breakthrough discoveries are about to happen? What is holding back stem cell treatments from reaching … |
|
Lack of demand forces uniQure to bail on gene therapy Glybera, marketing authorization in Europe to expire October 25
Seeking Alpha Citing a lack of demand, uniQure (NASDAQ:QURE) announces that it will not pursue a renewal of its European marketing authorization for Glybera (alipogene tiparvovec), set to expire on October 25. The European Commission OK’d the gene therapy for an … uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in EuropeGlobeNewswire (press release) Glybera Marketing Authorization Application Withdrawn In Europe and Other Selected CountriesYahoo Finance |
|
AGTC to Present at the 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
Nasdaq AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop treatments designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC’s product pipeline … |
Fortune |
Prepare for the Digital Health Revolution
Fortune And Crispr-Cas9 isn’t even the only type of Crispr out there: On April 12, researchers at the University of Texas Southwestern Medical Center announced they had successfully paired the gene-editing tool with a different kind of enzyme, called Cpf1, to … |
Asian Scientist Magazine |
CBMG & GE Healthcare Life Sciences Collaborate On Cancer Immunotherapy
Asian Scientist Magazine In connection with the collaboration, a joint laboratory within CBMG’s new Shanghai Zhangjiang GMP-facility will be established and dedicated to the joint research and development of a functionally integrated and automated immunotherapy cell … |